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Abstract.  Epithelia and mesenchyme interact during 
various physiologic and pathologic processes. Scatter 
factor is a mesenchyme-derived cytokine that stimu- 
lates motility, proliferation,  and morphogenesis of 
epithelia.  Recent studies suggest that scatter factor and 
its receptor (c-met)  mediate mesenchyme/epithelia sig- 
nalling and even interconversion.  In this mini-review, 
we will discuss how scatter factor and c-met may 
mediate interactions between mesenchyme and epithe- 
lia during embryogenesis, organ repair,  and neoplasia. 
PITHELIA and mesenchyme are morphologically and 
functionally distinct tissue types. Epithelial  cells are 
usually  immobile,  form  ordered  structures  (e.g., 
ducts,  skin,  alveoli),  and perform specialized  functions.  In 
contrast,  mesenchymal  cells are more mobile, form loose 
aggregations  within  the extracellular  matrices (ECMs) 1 of 
most organs, and usually perform supportive functions. Epi- 
thelia  and mesenchyme interact  by direct cell contact and 
by secreted proteins that convey a signal from one cell type 
to the other. One such protein is scatter factor (SF) (42). SF 
appears to play major roles in normal development, regener- 
ation, and carcinogenesis.  The emerging SF story raises im- 
triguing  questions  concerning  the parallels  between these 
processes. 
Scatter Factor and c-Met 
SF was identified  as a mesenchymal  cell-derived cytokine 
that dissociates ("scatters") cohesive colonies of epithelium 
into individual  cells (42).  Hepatocyte growth factor (HGF) 
was discovered as a mitogen for adult hepatocytes 07, 21). 
Later studies revealed that SF and HGF are identical (1, 47). 
SF is a heparin-binding  glycoprotein  consisting of a 60-kD 
u-chain and 30-kD/3-chain linked by disulfide bonds (6, 28). 
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SF belongs to the family of kringle proteins (21), character- 
ized by triple disulfide loop structures (kringles) that mediate 
protein/protein  and protein/cell  interactions.  Although  SF 
exhibits 38% sequence identity to the proenzyme plasmino- 
gen, it lacks protease activity due to two amino acid substitu- 
tions at the catalytic center of the/3-chain  (21). SF is synthe- 
sized  as  a  728-amino  acid  precursor  (preproSF)  and  is 
cleaved  intracellularly  to  its  secreted  single-chain  form 
(proSF), which is inactive. Extracellular  cleavage of proSF 
at ~arg-'95val, yields active two-chain SF (21). One enzyme 
capable of activating proSF is HGF activator,  a serine pro- 
tease related to coagulation  factor XII (16). This enzyme is 
secreted in zymogen form, and may be activated by a proteo- 
lyric cascade triggered  by tissue injury (18). 
The SF receptor is the c-met proto-oncogene product (3), 
a transmembrane  tyrosine ldnase that is expressed predomi- 
nantly on epithelial cells (8). The c-met receptor is a 190-kD 
glycoprotein  consisting  of a  145-kD  membrane-spanning 
/3-chain and a  50-kD ix-chain.  The extracellular  binding, 
membrane,  and tryosine kinase domains are located on the 
/3-chain. Two receptor tyrosine kinases  closely related  to 
c-met,  c-sea,  and Ron,  have been described (10, 27), but 
ligands for these receptors have not been identified.  Macro- 
phage-stimulating  protein, a serum protein that induces the 
motility  and  phagocytic  activity of macrophages  (51), is 
structurally  related  to SF and may be the ligand for one of 
these receptors. 
Biologic Activities of SF 
SF dissociates sheets of epithelia into individual cells, which 
often exhibit characteristics  of mesenchymal  cells,  such as 
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directed cell migration and invasion (1, 28, 30,  31, 42). SF 
up-regulates gene and protein expression of urokinase (uPA) 
and uPA receptor (9, 24, 31). The net effect is to put more 
uPA on the cell surface, where it may mediate focal degrada- 
tion of ECM to clear a path for invading cells. Thus, SF may 
"switch on" a program of cell activities for invasion.  SF is 
mitogenic  for various  normal  cell types,  including  mam- 
mary, epidermal, and bronchial epithelium (33). SF is also 
a potent morphogen. In the absence of SF, kidney epithelial 
cells incubated in collagen type I gels aggregate into cysts. 
In the presence of SF, these cells form a network of branch- 
ing tubules that exhibit correct apical-basolaterai  polarity 
(19, 35). Similarly, SF induces mammary epithelial cells to 
form duct-like structures (45). The morphogenic activity of 
SF may be modulated by the extracellular environment and 
by cell-specific programs of differentiation (see below). 
Regulation of SF Expression and Activity 
In vitro, the major SF-producing cell types are mesenchymal 
ceils,  including  fibroblasts,  vascular  smooth muscle cells, 
glial cells, macrophages,  and activated T lymphocytes (20, 
28, 32, 42). SF production by some human fibroblast strains 
is  stimulated  by IL-1  and TNFot (43),  cytokines that  up- 
regulate  the  inflammatory  response.  On  the  other  hand, 
TGF/3, which generally down-regulates the inflammatory re- 
sponse, inhibits SF production (7). Since IL-1, TNFot, and 
TGF/3 each exhibit a wide array of activities, the existence 
of a more specific class of SF regulators seems likely. Recent 
studies indicate that mammary  carcinoma cells, which do 
not produce SF, produce soluble factors distinct from IL-1 
and TNF that stimulate SF gene and protein expression by 
fibroblasts (31,  32, 38). At least two factors are produced, 
a high molecular weight (>30 kD) heat-labile protein and a 
low molecular weight (<30 kD) heat-stable protein.  A  12- 
kD SF-inducing protein with properties similar to the <30- 
kD factor secreted by breast carcinoma cells was recently 
purified and characterized  (32). 
Direct co-culture of fibroblasts and epithelia leads to down- 
regulation of SF gene expression by the fibroblasts (11, 38). 
This  phenomenon  may  reflect  a  homeostatic  mechanism 
to allow the stable coexistence of epithelia and mesenchyme 
in adult tissues. SF production is also down-regulated by cul- 
turing  fibroblasts and carcinoma  ceils in a  Millipore well 
chamber so that there is no direct cell contact (38).  Thus, 
a soluble inhibitor may be released as a result of interaction 
between the two cell types. The promoter region of the mu- 
rine SF gene is very large and complex (14). This region con- 
tains IL-6 response elements, binding sites for NF-IL6 (con- 
sistent with the sensitivity of fibroblasts to IL-1 and TNF), 
a TGF/3 inhibitory element, a cAMP response element, es- 
trogen  response  elements,  cell type-specific transcription 
factor binding sites, and multiple positive and negative regu- 
latory elements for which transcription factors have not been 
identified.  The  identification  of SF  regulators,  their  re- 
ceptors, and the relevant transcription factors will undoubt- 
edly enhance  the  understanding  of mesenchyme/epithelia 
communication. 
Some fibroblast lines produce a truncated form of SF con- 
sisting of the NH~-terminai region and the first two kringle 
domains (NK2) (4). NK2, which is generated by alternative 
mRNA splicing, binds to c-met receptor with high affinity 
and blocks SF mitogenic activity. It is not known if NK2 can 
serve as a physiologic regulator of SE An epithelial junction- 
promoting activity has been detected in medium from Nil8 
hamster fibroblasts (41). This activity causes scattered colo- 
nies of mammary epithelia to revert to a cohesive morphol- 
ogy. A similar activity is found in extracts of mouse tissues 
that lack SF activity (31). These studies suggest the existence 
of active mechanisms  for down-modulation of SF biologic 
action. 
c-Met Signal Transduction 
Under different conditions, SF may direct cells toward motil- 
ity, proliferation, or morphogenesis. These activities are not 
mutually exclusive. Branching morphogenesis in a collagen 
matrix  involves motility,  invasion,  expression of proteases 
that mediate cell invasion (e.g., uPA), and tubule formation. 
Studies using chimeric receptors containing the extracellular 
and membrane domains of other ligands fused to the intra- 
cellular portion of c-met demonstrate that the c-met receptor 
tyrosine kinase  can transduce  multiple biologic functions 
(48). The activation of distinct pathways for motility, growth, 
and/or  morphogenesis  may be determined  at the receptor 
level or more distally. 
Specificity at the receptor level may be achieved by dif- 
ferential binding of phosphotyrosines of the activated recep- 
tor  with  cytoplasmic  signaling  proteins.  These  proteins 
recognize specific tyrosine-phosphorylated regions of a re- 
ceptor via their src-homology region 2 (SH2) domains (13). 
The specificity of this  interaction  is determined,  in part, 
by the three amino acids that immediately follow the recep- 
tor phosphotyrosines.  A multifunctional  site involving two 
YV(H/N)V  motifs  mediates  the  binding  of  c-met  to 
phosphatidylinositol-3'-kinase (PI3K), protein tyrosine phos- 
phatase  2,  phospholipase  C-7,  pp60  ....  and  grb2/hSosl 
(25). Homologous sequences are found in met-related recep- 
tors, but not in EGF, PDGF, or other growth factor receptors 
(25). The binding of signaling proteins to this site may vary 
as a function of the binding affinity of specific SH2 domains, 
local concentration of signaling molecule, and level of c-met 
receptor phosphorylation. Although PI3K binds to the YV(H/ 
N)V  site,  this  site does not contain  known consensus  se- 
quences for binding of COOH- or NH2-terminal  SH2 do- 
mains  of PI3K.  c-Met contains  four other potential phos- 
phorylation sites, none of which contain known SH2 binding 
consensus sequences. By analogy, these sites may mediate 
binding to known or as yet undiscovered signaling proteins. 
The ECM may play a major role in directing c-met signal- 
ing.  SF-induced tubule formation by MDCK cells is facili- 
tated by some ECM molecules (collagen I, laminin) and in- 
hibited by others (heparan  sulfate proteoglycans [HSPGs], 
collagen IV) (34). TGF~, which is often found in basement 
membrane, inhibits branching morphogenesis. Morphogen- 
esis is a vectorial process, and may depend upon the local 
concentrations of ECM proteins, SE and other growth fac- 
tors.  Collagen I or laminin at the leading edge of a tubule 
may promote forward extension, while inhibitory molecules 
(e.g.,  collagen IV)  may promote branching.  These events 
may be modified by cell surface and ECM HSPGs, which 
bind SF and alter its bioavailability.  The binding of ECM 
proteins to integrins is known to activate intracellular signal- 
ing events, including tyrosine phosphorylation (37). SF up- 
regulates adhesion of EMT6 mouse mammary tumor cells to 
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(31). Thus, SF may induce expression of a particular set of 
integrins that allows the ECM to modulate intracellular sig- 
naling. Studies using pharmacologic agents that alter signal 
transduction suggest that the scattering and morphogenetic 
responses of MDCK cells are modulated by multiple phos- 
phorylation pathways, including those involving protein ki- 
nases A and C (29,  35).  c-Met itself contains a consensus 
phosphorylation sequence of  PKC, and c-met activation is in- 
hibited by phosphorylation of this site (5).  Thus, the ECM 
may regulate c-met signaling by inducing phosphorylation of 
sites on c-met or other signalling molecules (Fig.  1). 
The ability of SF to dissociate epithelia has focused atten- 
tion on its effects on adhesion molecules, including cadhe- 
rins. Cadherin function is modulated by catenins and other 
proteins that bind to the cytoplasmic domain of cadherin 
molecules and link them to the cytoskelton (23). SF may in- 
hibit the function of cadherins by altering the phosphor- 
ylation of cadherin-associated proteins. SF induces tyrosine 
phosphorylation of/~-catenin,  which  may  down-regulate 
cadherin-mediated cell adhesion (39).  Specific src family 
tyrosine kinases are known to be localized at adherens junc- 
tions (46),  raising the possibility that scattering is due, in 
part, to phosphorylation of junctional proteins by the SF- 
activated c-met receptor. Cadherin adhesive function is im- 
paired in carcinomas,  especially, in poorly differentiated, 
highly invasive tumors (2).  The biologic effects of SF may 
be influenced by the number, type, and quality of intercellu- 
lar junctions. Thus, SF might promote dissociation and inva- 
sion in poorly differentiated tumors (see below), but might 
induce  glandular formation in  well-differentiated tumors 
with intact adhesive mechanisms. 
SF/c-Met in Mesenchymal/Epithelial Interaction 
during Physiologic and Pathologic Processes 
Embryogenesis. Epithelia/mesenchyme  interconversion is 
an important theme in early embryogenesis. As described 
earlier, SF mediates conversion of sheets of epithelium into 
individual, fibroblast-like cells and, under other conditions, 
mediates organization of epithelial cells into ordered, tubu- 
lar structures. When 3T3 mouse fibroblasts are transfected 
with human SF and c-met cDNAs and induced to express 
high levels of SF and c-met protein, these cells from duct- 
like structures, express cytokeratins, and form epithelial-like 
intercellular junctions  (44).  During  mouse development, 
c-met mRNA is expressed in epithelial cells of  various organs, 
while SF mRNA is expressed in mesenchymal cells in close 
proximity to these epithelial cells (40).  In the developing 
kidney, SF and c-met are highly expressed at day 11.5, corre- 
sponding to the onset of tubulogenesis and branching mor- 
phogenesis (36). Moreover, an antiserum against SF inhibits 
kidney development in organ culture (36).  Thus, the SF/ 
c-met ligand-receptor pathway may transduce mesenchyme/ 
epithelial signaling and conversion during embryogenesis. 
Misfunctioning of this pathway may contribute to cystic dis- 
eases of epithelia, such as polycystic kidney disease. 
Organ Regeneration.  SF has been studied as a potential 
organotropic factor for regeneration of injured liver and kid- 
ney (12, 15). When two-thirds of the rat liver is reseeted, the 
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Figure  /.  Possible mecha- 
nism(s) of SF-induced mor- 
phogenesis. If c-met signaling 
occurs primarily through the 
multifunctional site (VV) (see 
text), then environmental  con- 
text is likely to be critical in 
determining the cell response. 
In the model shown, morpho- 
genesis  is  activated by  SF/ 
c-met  only  when  specific 
matrix-integrin  interactions 
occur. These interactions are 
presumed to modify the PTyr 
state of c-met,  either at the 
VV  site or at  a  different site 
(X),  leading to  coordinated 
changes in protease, protease 
inhibitor, ECM, and integrin 
expression. The c-met recep- 
tor  also  modifies cadherin- 
mediated  intercellular adhe- 
sion through phosphorylation 
of &catenin. Accessory  growth 
factors  may  exert stimula- 
tory  (+)  or  inhibitory  (-) 
influences on morphogenesis 
through  their receptors (GFRs), 
by altering c-met signaling or 
by independent  pathways. Cell/ 
matrix  interactions  control 
branching vs. forward  extension of  tubules (fight half  of  figure), as described in the text. Additional  modulation  might occur through regula- 
tion of exchangeable pools of growth factors bound to ECM and to the cell surface. 
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within 10 d. After resection, SF mRNA expression is up- 
regulated and peaks by 24 h, followed by a wave of hepato- 
cyte DNA  synthesis and cell division. High levels of SF 
appear in the blood ~6 h after surgery, too early to be ex- 
plained solely by synthesis in the liver. The early appearance 
of SF may be due to release of SF stored bound to heparin- 
like residues in the ECM and to synthesis of SF in distant 
uninjured organs (e.g., lung, kidney, spleen). While these 
studie  s implicate SF in organ regeneration, a definitive role 
for SF as an "instigator" rather than a  "bystander" is not 
proven. 
In situ hybridization studies suggest that the major SF- 
producing cells in the liver are mesenchymal cells, including 
Kupffer (macrophage-like) cells and sinusoidal endothelium 
(22).  Following liver  injury, pulmonary alveolar  macro- 
phages and endothelial cells are stimulated to produce SF 
(50).  Mesenchyme/epithelia  interactions  contributing  to 
liver regeneration might be of two types: (a) SF produced 
by local or distant mesenchymal cells induces proliferation 
of hepatocytes and biliary epithelium; and (b) SF inducers 
secreted by injured liver epithelium stimulate SF production 
by hepatic or distant mesenchymal  cells. Although SF is pro- 
duced at injured and distant sites, only epithelia of the in- 
jured organ are stimulated to proliferate. Mechanisms that 
prevent epithelial proliferation in uninjured organs are not 
well characterized, but could involve junction promoting 
proteins, as described above. 
Angiogenesis.  Recent studies indicate that SF is a power- 
ful inducer of angiogenesis (9, 20),  a process required for 
both embryogenesis and organ regeneration. Moreover, SF 
may contribute to the genesis of AIDS Kaposi's sarcoma 
(KS) (20), a cytokine-dependent neoplasm characterized by 
a major component of neovascularization. SF induces con- 
version of normal human endothelial cells to a KS tumor 
cell-like phenotype and functions as an autocrine growth fac- 
tor for cultured KS tumor ceils. Both SF and the c-met recep- 
tor are expressed by KS tumor cells and other cell types 
within KS lesions in vivo. Moreover, SF appears to be a ma- 
jor angiogenic and growth-stimulatory molecule present in 
conditioned medium  from retrovirus-infected T  lympho- 
cytes, which is required for long-term cultivation of KS tu- 
mor cells. 
Neoplasia.  A  role  for SF  as  a  mediator of neoplastic 
progression is suggested by the observations that: SF stimu- 
lates the motility and invasiveness of carcinoma cells (30, 
31); SF induces angiogenesis (9), which is necessary for the 
growth and metastasis of solid tumors; and the SF receptor 
is encoded by a proto-oncogene (3). This role is further sup- 
ported by several experimental and clinical studies. Mouse 
3T3 cells induced to overexpress c-met become tumorigenic; 
and constitutive overexpression of  both c-met and SF confers 
increased tumorigenicity via an autocrine loop (26).  SF en- 
hances the metastatic phenotype of mammary carcinoma 
cells in an in vivo murine model (31). SF is overexpressed 
in tumors, and a high level of SF in primary breast cancers 
is a strong, independent predictor of relapse and death (49). 
Overproduction of SF in tumors may be due to an abnormal 
mesenchymal/epithelial interaction  in  which  tumor  cells 
overexpress factors that induce SF production by stromal 
calls (31, 32, 38).  The putative contributions of SF, c-met, 
and SF inducers to tumor progression is a fertile area for fu- 
ture research. 
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